optimizing treatment with egfr inhibitors in colorectal cancer
Published 10 years ago • 357 plays • Length 4:00Download video MP4
Download video MP3
Similar videos
-
8:14
optimizing treatment with regorafenib in metastic colorectal cancer
-
7:32
considerations when selecting an egfr inhibitor in metastatic colorectal cancer
-
20:02
optimizing strategies for the treatment of colorectal cancer in the biomarker era
-
5:09
egfr therapy as upfront colorectal cancer treatment
-
16:56
colorectal cancer with acquired resistance to egfr antibodies: how to manage?
-
34:51
personalizing and optimizing patient care in metastatic colorectal cancer
-
6:59
optimizing frontline chemotherapy in metastatic colorectal cancer
-
5:42
optimizing care in metastatic colorectal cancer
-
28:29
metastatic colorectal cancer: optimizing dosing strategy for late-line therapies
-
35:27
expert perspectives: optimizing late-line therapy for patients with metastatic colorectal cancer
-
5:30
treatment options for advanced colorectal cancer
-
7:10
upfront egfr therapy in metastatic colorectal cancer
-
1:50
dr. benson on sequencing strategies with cetuximab in crc
-
8:47
colorectal cancer: dosing strategies with regorafenib
-
13:11
treatment sequencing in metastatic colorectal cancer
-
2:01
clarifying the mechanism of egfr inhibition in kras g13d colorectal cancer
-
2:14
anti-egfr rechallenge therapy with or without trametinib in addition to panitumumab in advanced crc
-
4:28
introduction: bevacizumab versus cetuximab in metastatic colorectal cancer
-
2:10
anti-egfr therapy for ras wild-type left-sided colorectal cancer